Use of convalescent plasma in COVID‐19 patients with immunosuppression

In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel coronavirus disease 19 (COVID‐19), including among patients with innate or acquired immunosuppression. However, the assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Senefeld, Jonathon W., Klassen, Stephen A., Ford, Shane K., Senese, Katherine A., Wiggins, Chad C., Bostrom, Bruce C., Thompson, Michael A., Baker, Sarah E., Nicholson, Wayne T., Johnson, Patrick W., Carter, Rickey E., Henderson, Jeffrey P., Hartman, William R., Pirofski, Liise‐anne, Wright, R. Scott, Fairweather, De Lisa, Bruno, Katelyn A., Paneth, Nigel S., Casadevall, Arturo, Joyner, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242637/
https://www.ncbi.nlm.nih.gov/pubmed/34036587
http://dx.doi.org/10.1111/trf.16525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242637/
https://www.ncbi.nlm.nih.gov/pubmed/34036587
http://dx.doi.org/10.1111/trf.16525

Ejemplares similares